DOCSLIB.ORG

Clues to the Mechanism Underlying Dopamine Cell Death in Parkinson's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clues to the Mechanism Underlying Dopamine Cell Death in Parkinson's Disease J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.52.Suppl.22 on 1 June 1989. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry. Special Supplement 1989:22-28 Clues to the mechanism underlying dopamine cell death in Parkinson's disease P JENNER From the Parkinson's Disease Society Research Centre, University Department ofNeurology, Institute of Psychiatry and King's College Hospital Medical School, London UK SUMMARY The primary pathological change in Parkinson's disease is the destruction of dopamine containing cells in the zona compacta of substantia nigra. The cause of nigral cell death and the underlying mechanism remains elusive. However, the discovery of the selective nigral neurotoxin MPTP and its ability to inhibit mitochondrial energy metabolism via its metabolite MPP+ and to generate superoxide radicals suggests processes by which nigral cell death might occur. Recent post- mortem evidence in brain tissue from patients dying with Parkinson's disease also suggests the occurrence of some on-going toxic mechanism. This may be a free radical process stimulated by an excess ofiron within subsantia nigra coupled to a generalised decrease in brain ferritin content. These data suggest altered iron handling occurs in Parkinson's disease which may lead to the generation of toxic oxygen species such as superoxide radicals. There is also evidence for an inhibition ofProtected by copyright. mitochondrial function in the substantia nigra in patients with Parkinson's disease. So there may be a close association between the actions of the synthetic neurotoxin MPTP and the underlying cause of idiopathic Parkinson's disease. There are widespread pathological and biochemical However, MPTP does not provide an exact model changes in the brain ofpatients dying with Parkinson's of idiopathic Parkinson's disease since in general disease.'2 The primary alteration appears to be a loss neurotoxic effects are limited to substantia nigra and of dopamine containing cells in zona compacta of its corresponding losses of caudate-putamen substantia nigra with a corresponding generalised loss dopamine content.78 Overall other neuronal systems of dopamine content throughout the forebrain. While do not appear to be involved and there is no the details of these changes are extensively documen- occurrence of Lewy bodies as a marker of the process ted3 there has been little evidence as to the underlying underlying idiopathic Parkinson's disease.'"'2 One cause of dopamine cell death or the mechanism by reason for the discrepancies between MPTP induced which dopamine cells degenerate. Many theories have Parkinsonism and the idiopathic disease may relate to been advanced (for example, involvement of viruses, the age ofthe animals studied. In general, young adult aberrant metabolism of dopamine, involvement of primates are used in such experiments but where older neuromelanin) but none of these proven. More recen- animals have been employed the pathology has been http://jnnp.bmj.com/ tly interest has centred on the manner in which more extensive, involving also the locus coeruleus and endogenous or environmental toxins may be involved Lewy body like inclusions have been observed.'"'5 as a cause of Parkinson's disease. This stems from the However, MPTP has provided the most appropriate discovery of the selective nigral toxin, I-methyl-4- animal model of Parkinson's disease so far devised. It phenyl-1,2,3,6-tetrahydropyrdine (MPTP) which was has found use as a test-bed in which to evaluate novel found to induce persistent Parkinsonism in man and therapies for Parkinson's disease'"'9 and also to other primate species by destroying dopamine con- evaluate long-term complications of levodopa treat- taining cells within substantia nigra.' ment of Parkinson's disease.20'2 Similarly, MPTP on October 1, 2021 by guest. The discovery of MPTP provided a major impetus treated primates provide an ideal test-bed in which to for research into the cause of Parkinson's disease. evaluate the usefulness of the implantation of foetal nigral dopamine containing cells as a "cure" for Parkinson's disease.2223 However, it may be one other Address for reprint requests: Dr P Jenner, Department ofNeurology, aspect of the actions of MPTP which is the most Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK. important, namely the mechanism by which MPTP Accepted March 1989 kills nigral dopamine containing cells. This may 22 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.52.Suppl.22 on 1 June 1989. Downloaded from Clues to the mechanism underlying dopamine cell death in Parkinson's disease 23 provide clues to the selective vulnerability of this cell free radicals. This was derived from the chemical group and to the pathological process underlying similarity between MPP+ and a paraquat, a known dopamine cell death in Parkinson's disease. redox cycler. Although MPP+ bears a striking chemical resemblance to paraquat, MPP+ is extremely Mechanism ofaction ofMPTP stable compared with paraquat and does not undergo Many important steps in the mechanism of action of single electron reduction to produce oxygen MPTP have been uncovered. Following the adminis- radicals.474 This is emphasised by the electrochemical tration ofMPTP to primates it was found that another potential of MPP+ of < 1-0 V which compared with substance, namely, l-methyl-4-phenyl-pyridinium paraquat makes it improbable that it will undergo species (MPP+), and not MPTP itself, accumulated bioreduction to stimulate toxic oxygen radical for- and persisted within the brain.2425 The reason for this mation.49 However, this conclusion presumes that it is became clear when it was discovered that MPTP was MPP+ alone which causes the neurotoxicity associated an unexpected substrate for MAO B2"2' So it appeared with MPTP administration. that MPP+ rather than MPTP might be the neurotoxic MPTP is converted to MPP+ in a two-stage reaction species. Indeed, MPP+ was actively accumulated by via the intermediate dihydropyridine derivative, dopaminergic neurons since it is a substrate for MPDP+."52 This sequence ofevents gives more scope dopamine reuptake mechanisms29 and this accumula- for the production of oxygen species. Indeed, there is tion may be enhanced by an association with recent evidence that oxygen radicals may be involved neuromelanin.? MPTP neurotoxicity could be preven- in the toxicity of MPTP in a manner previously ted by prior treatment of animals with MAO B unsuspected. Thus, in aerobic mitochondrial prepara- inhibitors, such as deprenyl, or dopamine reuptake tions MPTP stimulated an electron spin resonance blockers, such as nomifensine.3"32 Also, MPP+ was (ESR) signal compatible with free radical formation.53 more toxic than MPTP itself in destroying dopamine This signal was prevented by inclusion of superoxide containing cells. Thus, intranigral infusions of MPP+, dismutase suggesting the generation of superoxide Protected by copyright. but not MPTP, destroyed nigral neurones in rats.33 radicals. The metabolism of MPTP appeared involved Similarly, intracerebroventricular injections of MPP+ since the ESR signal was prevented by the inclusion of destroyed nigral cells in the brains of mice.? In cell the MAO B inhibitor deprenyl but not by the MAO A culture MPP+ is toxic to mesencephalic cells.35 36 So all inhibitor clorgyline. In the absence of mitochondria this data led to the conclusion that it was MPP+ and neither of the MPTP metabolites, MPP+ or MPDP+, not MPTP that was responsible for the toxic actions alone produced an ESR signal. However, together observed. they caused a spectrum which increased in intensity These data did not, however, explain the mechanism with time. These data suggest a redox reaction occurs by which MPTP (or MPP+) killed dopamine contain- between MPP+ and MPDP+ to produce toxic oxygen ing cells. This issue was clarified with the discovery radicals and that these may be involved in the ability of that MPP+ induces oxidative stress owing to its ability MPTP to destroy nigral containing cells. Whether an to inhibit the oxidation ofmitochondrial NAD-linked action of MPTP based on superoxide formation is substrates.373' More specifically MPP+ inhibits mito- compatible with inhibition of mitochondrial function chondrial energy metabolism at the level of complex remains to be determined. I3. However, millimolar concentrations ofMPP+ were So the MPTP story reveals possible mechanisms by required in vitro to produce this effect and it was which nigral dopamine containing cells may be des- thought unlikely that these would be achieved in vivo. troyed. But what is its relevance to Parkinson's http://jnnp.bmj.com/ But MPP+ is actively accumulated by mitochondria disease? It may be that there is an MPTP like toxin such that 50-100 times the external concentration can involved as a cause of Parkinson's disease although at be achieved.A"2 So at present it is believed that MPP+ present this appears unlikely. On the other hand, it interferes with mitochondrial energy metabolism may be that the mechanism by which MPTP kills somewhere between NADH dehydrogenase and co- dopamine cells by interference with mitochondrial enzyme Q 10.43 Exactly how and where this occurs function or by superoxide formation may reflect a remains unknown. Nevertheless, its consequences can selective vulnerability of dopamine cells in substantia be observed in terms of depletion of cellular ATP, a nigra which is also apparent in idiopathic Parkinson's on October 1, 2021 by guest. decrease in reduced glutathione content, and altera- disease. So, are there any similarities between the tions in cellular calcium content."44" actions of MPTP and biochemical changes occurring in brain in Parkinson's disease itself? Free radical generation as a mechanism of MPTP toxicity Evidencefor a neurotoxic process occurring in brain in One basic mechanism initially proposed to explain the Parkinson's disease neurotoxic actions of MPP+ was the production of One approach to detecting a cause or mechanism J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.52.Suppl.22 on 1 June 1989.
Load more

Recommended publications
  • 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Hydrochloride (M0896)
    1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Product Number M 0896 Store at Room Temperature Product Description References 1. The Merck Index, 12th ed., Entry# 6376. Molecular Formula: C12H15N • HCl 2. Przedborski, S., et al., The parkinsonian toxin Molecular Weight: 209.7 MPTP: action and mechanism. Restor. Neurol. CAS Number: 23007-85-4 Neurosci., 16(2), 135-142 (2000). Synonym: MPTP • HCl 3. Adams, J. D., Jr., et al., Parkinson's disease - redox mechanisms. Curr. Med. Chem., 8(7), 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 809-814 (2001). is a piperidine derivative and dopaminergic neurotoxin 4. Ziering, A., et al., Piperidine Derivatives. Part III. that has been used in neurological research. MPTP is 4-Arylpiperidines. J. Org. Chem., 12, 894-903 metabolized to 1-methyl-4-phenylpyridine (MPP+), (1947). which in turn can cause free radical production in vivo 5. Schmidle, C. J., and Mansfield, R. C, The and lead to oxidative stress. Thus MPP+ is generally aminomethylation of olefins. IV. The formation of acknowledged as the active metabolite derived from 1-alkyl-4-aryl-1,2,3,6-tetrahydropyridines. J. Am. MPTP.2,3 The synthesis of MPTP has been Chem. Soc., 78, 425-428 (1956). reported.4,5 6. Davis, G. C., et al., Chronic Parkinsonism secondary to intravenous injection of meperidine MPTP is widely utilized in in vivo research studies as a analogues. Psychiatry Res., 1, 249-254 (1979). model for Parkinsonism.6-11 A mouse investigation of 7. Burns, R. S., et al., A primate model of MPTP treatment has indicated a possible role for parkinsonism: selective destruction of cyclooxygenase 2 (COX-2) in Parkinsonian dopaminergic neurons in the pars compacta of the neurodegeneration.12 A review describes the substantia nigra by N-methyl-4-phenyl-1,2,3,6- application of MPTP studies to programmed cell death tetrahydropyridine.
    [Show full text]
  • Mechanistic Comparison Between MPTP and Rotenone Neurotoxicity in Mice T ⁎ Sunil Bhurtel, Nikita Katila, Sunil Srivastav, Sabita Neupane, Dong-Young Choi
    Neurotoxicology 71 (2019) 113–121 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Full Length Article Mechanistic comparison between MPTP and rotenone neurotoxicity in mice T ⁎ Sunil Bhurtel, Nikita Katila, Sunil Srivastav, Sabita Neupane, Dong-Young Choi Yeungnam University, 280 Daehak-Ro, Gyeongsan, Gyeongbuk, 38541, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Animal models for Parkinson’s disease (PD) are very useful in understanding the pathogenesis of PD and MPTP screening for new therapeutic approaches. 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and rotenone Rotenone are common neurotoxins used for the development of experimental PD models, and both inhibit complex I of ’ Parkinson s disease mitochondria; this is thought to be an instrumental mechanism for dopaminergic neurodegeneration in PD. In Neurotrophic factors this study, we treated mice with MPTP (30 mg/kg/day) or rotenone (2.5 mg/kg/day) for 1 week and compared the neurotoxic effects of these toxins. MPTP clearly produced dopaminergic lesions in both the substantia nigra and the striatum as shown by loss of dopaminergic neurons, depletion of striatal dopamine, activation of glial cells in the nigrostriatal pathway and behavioral impairment. In contrast, rotenone treatment did not show any significant neuronal injury in the nigrostriatal pathway, but it caused neurodegeneration and glial activation only in the hippocampus. MPTP showed no such deleterious effects in the hippocampus suggesting the higher susceptibility of the hippocampus to rotenone than to MPTP. Interestingly, rotenone caused upregulation of the neurotrophic factors and their downstream PI3K-Akt pathway along with adenosine monophosphate-activated protein kinase (AMPK) activation.
    [Show full text]
  • Ecstasy: the Clinical, Pharmacological and Neurotoxicological Effects of the Drug Mdma Topics in the Neurosciences
    ECSTASY: THE CLINICAL, PHARMACOLOGICAL AND NEUROTOXICOLOGICAL EFFECTS OF THE DRUG MDMA TOPICS IN THE NEUROSCIENCES Other books in the series: Rahamimoff, Rami and Katz, Sir Bernard, eds.: Calcium, Neuronal Function and Transmitter Release. ISBN 0-89838-791-4. Fredrickson, Robert C.A., ed.: Neuroregulation of Autonomic, Endocrine and Immune Systems. ISBN 0-89838-800-7. Giuditta, A., et al., eds.: Role of RNA and DNA in Brain Function. ISBN 0-89838-814-7. Stober, T., et al.,: Central Nervous System Control of the Heart. ISBN 0-89838-820-l. Kelly J., et al., eds.: Polyneuropathies Associated with Plasma Cell Dyscrasias. ISBN 0-89838-884-8. Galjaard, H. et al., eds.: Early Detection and Management of Cerebral Palsy. ISBN 0-89838-890-2. Ferrendelli, J., et al., eds.: Neurobiology of Amino Acids, Pep tides and Trophic Factors. ISBN 0-89838-360-9. ECSTASY: THE CLINICAL, PHARMACOLOGICAL AND NEUROTOXICOLOGICAL EFFECTS OF THE DRUGMDMA Edited by STEPHEN J. PEROUTKA Stanford University Medical Center ~. KLUWER ACADEMIC PUBLISHERS "BOSTON IDORDRECHT ILONDON Distributors for North America: Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park, Norwell, MA, 02061, USA for all other countries: Kluwer Academic Publishers Group, Distribution Centre, Post Office Box 322, 3300 AH Dordrecht, The Netherlands Library of Congress Cataloging-in-Publication Data Ecstasy: the clinical, pharmacological, and neurotoxicological effects of the drug MDMA / edited by Stephen]. Peroutka. p. cm. - (Topics in the neurosciences; TNSC9) Includes bibliographies and index. ISBN- 13:978- I -4612-8799-5 e-ISBN-13:978- I -4613-1485-1 DOl: 10.1007/978-1-4613-1485-1 1. MDMA (Drug) 2.
    [Show full text]
  • Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
    The Journal of Neuroscience, October 8, 2003 • 23(27):9107–9115 • 9107 Behavioral/Systems/Cognitive 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates Mahmoud M. Iravani, Michael J. Jackson, Mikko Kuoppama¨ki, Lance A. Smith, and Peter Jenner Neurodegenerative Disease Research Centre, Guy’s, King’s, and St. Thomas’ School of Biomedical Sciences, King’s College, London SE1 1UL, United Kingdom Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of L-3,4-dihydroxyphenylalanine (L-DOPA) while suppressing dyskinesia in a single patient with Parkinson’s disease (PD). The clinical basis of this effect of MDMA is unknown but may relate to its actions on either dopaminergic or serotoninergic systems in brain. In normal, drug-naive common marmosets, MDMA administration suppressed motor activity and exploratory behavior. In 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated, L-DOPA-primedcommonmarmosets,MDMAtransientlyrelievedmotordisability but over a period of 60 min worsened motor symptoms. When given in conjunction with L-DOPA, however, MDMA markedly decreased dyskinesia by reducing chorea and to a lesser extent dystonia and decreased locomotor activity to the level observed in normal animals. MDMA similarly alleviated dyskinesia induced by the selective dopamine D2/3 agonist pramipexole. The actions of MDMA appeared to be mediated through 5-HT mechanisms because its effects were fully blocked by the selective serotonin reuptake inhibitor fluvoxamine. Furthermore,theeffectofMDMAon L-DOPA-inducedmotoractivityanddyskinesiawaspartiallyinhibitedby5-HT1a/bantagonists.The ability of MDMA to inhibit dyskinesia results from its broad spectrum of action on 5-HT systems.
    [Show full text]
  • Designer-Drugs-China-White-And-MPTP.Pdf
    Selected Papers of William L. White www.williamwhitepapers.com Collected papers, interviews, video presentations, photos, and archival documents on the history of addiction treatment and recovery in America. Citation: White, W. (2014). Designer drugs, China white, and the story of MPTP. Posted at www.williamwhitepapers.com Designer Drugs, China White, and the Story of MPTP William L. White Emeritus Senior Research Consultant Chestnut Health Systems [email protected] NOTE: The original 1,000+ page manuscript for Slaying the Dragon: The History of Addiction Treatment and Recovery in America had to be cut by more than half before its first publication in 1998. This is an edited excerpt that was deleted from the original manuscript. "Designer drugs"--a term coined by The modern story of designer drugs pharmacologist Gary Henderson, of the begins in 1976 with Barry, a bright, twenty- University of California--represent efforts by three-year-old college student from chemists to alter the molecular structure of a Bethesda, Maryland. Barry created an psychoactive drug to change the drug analogue of meperidine (Demerol)--MPPP, identity while maintaining or intensifying the that was not legally controlled as a way to original drug's psychoactive properties. avoid contact with the illicit drug market. He Designer drugs are often analogues-- continued to synthesize and use MPPP for chemical cousins--of the drugs they’re six months without incident. In the summer modeled after and may have effects and of 1976, he made a new batch of MPPP but risks quite different than these original through a mistake in the synthesis procedure substances.
    [Show full text]
  • Signaling Plays an Important Role in MPTP-Induced Neuronal Death
    Cell Death and Differentiation (2016) 23, 542–552 & 2016 Macmillan Publishers Limited All rights reserved 1350-9047/16 www.nature.com/cdd c-Abl–p38α signaling plays an important role in MPTP-induced neuronal death RWu1,2, H Chen1,3,JMa1,2,QHe1,2, Q Huang4, Q Liu5, M Li*,4 and Z Yuan*,1,2,3 Oxidative stress is a major cause of sporadic Parkinson’s disease (PD). Here, we demonstrated that c-Abl plays an important role in oxidative stress-induced neuronal cell death. C-Abl, a nonreceptor tyrosine kinase, was activated in an 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine hydrochloride (MPTP)-induced acute PD model. Conditional knockout of c-Abl in neurons or treatment of mice with STI571, a c-Abl family kinase inhibitor, reduced the loss of dopaminergic neurons and ameliorated the locomotive defects induced by short-term MPTP treatment. By combining the SILAC (stable isotope labeling with amino acids in cell culture) technique with other biochemical methods, we identified p38α as a major substrate of c-Abl both in vitro and in vivo and c-Abl- mediated phosphorylation is critical for the dimerization of p38α. Furthermore, p38α inhibition mitigated the MPTP-induced loss of dopaminergic neurons. Taken together, these data suggested that c-Abl–p38α signaling may represent a therapeutic target for PD. Cell Death and Differentiation (2016) 23, 542–552; doi:10.1038/cdd.2015.135; published online 30 October 2015 Parkinson’s disease (PD), the second most common neuro- cell signaling activities, including growth factor signaling, cell degenerative disorder,
    [Show full text]
  • Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration
    8138 • The Journal of Neuroscience, July 25, 2007 • 27(30):8138–8148 Neurobiology of Disease Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration W. Michael Caudle,1,2 Jason R. Richardson,1,2,3 Min Z. Wang,1,2 Tonya N. Taylor,1,2 Thomas S. Guillot,1,2 Alison L. McCormack,4 Rebecca E. Colebrooke,5 Donato A. Di Monte,4 Piers C. Emson,5 and Gary W. Miller1,2 1Center for Neurodegenerative Disease, 2Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, 3Department of Environmental and Occupational Medicine, University of Medicine and Dentistry-New Jersey/Robert Wood Johnson Medical School and Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey 08854, 4The Parkinson’s Institute, Sunnyvale, California 94089, and 5The Babraham Institute, Neurobiology Programme, Babraham, Cambridge CB2 4AT, United Kingdom The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the dopamine system. Here, we show that mice that express ϳ5% of normal VMAT2 (VMAT2 LO) display age-associated nigrostriatal dopamine dysfunction that ultimately results in neurodegeneration. Elevated cysteinyl adducts to L-DOPA and DOPAC are seen early and are followed by increased striatal protein carbonyl and 3-nitrotyrosine formation. These changes were associated with decreased striatal dopamine and decreased expression of the dopamine transporter and tyrosinehydroxylase.Furthermore,weobservedanincreasein␣-synucleinimmunoreactivityandaccumulationandneurodegeneration in the substantia nigra pars compacta in aged VMAT2 LO mice. Thus, VMAT2 LO animals display nigrostriatal degeneration that begins in the terminal fields and progresses to eventual loss of the cell bodies, ␣-synuclein accumulation, and an L-DOPA responsive behavioral deficit, replicating many of the key aspects of Parkinson’s disease.
    [Show full text]
  • Exposure of Mice to Tobacco Smoke Attenuates the Toxic Effect of Methamphetamine on Dopamine Systems
    Toxicology Letters 118 (2000) 43–46 www.elsevier.com/locate/toxlet Exposure of mice to tobacco smoke attenuates the toxic effect of methamphetamine on dopamine systems Stephen C. Bondy a,*, Syed F. Ali b, Michael T. Kleinman a a Center for Occupational and En6ironmental Health, Department of Community and En6ironmental Medicine, Uni6ersity of California, Ir6ine, CA 92697-1820, USA b Di6ision of Neurotoxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA Received 26 May 2000; received in revised form 28 August 2000; accepted 29 August 2000 Abstract Methamphetamine treatment of mice rapidly and severely depleted levels of dopamine and its metabolites, homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in the caudate nucleus. Exposure of mice to cigarette smoke by means of nose-only breathing apparatus for 20 min twice daily over 3 days prior to drug treatment significantly attenuated the neurotoxicity of methamphetamine as judged by a lesser depletion of dopamine, DOPAC and HVA. The lesser effect of methamphetamine upon content of serotonin level was unaltered by prior inhalation of smoke. Results suggest a specific protective effect of inhaled tobacco smoke upon the effects of methamphetamine upon dopaminergic circuitry. © 2000 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Tobacco smoke; Nicotine; Methamphetamine; Dopamine; Cigarettes; Parkinson’s disease 1. Introduction 1999). Environmental factors may contribute to- ward the incidence of Parkinson’s disease (PD) There are several reports concerning the protec- (Langston, 1998), and MPTP and metham- tive properties of nicotine upon the dopaminergic phetamine provide useful animal models for some system following its exposure to specific toxins. aspects of this neurodegenerative disorder.
    [Show full text]
  • KDS2010, a Newly Developed Reversible MAO-B Inhibitor, As an Effective Therapeutic Candidate for Parkinson’S Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190579; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s disease Min-Ho Nam1†, Jong-Hyun Park2†, Hyo Jung Song2†, Ji Won Choi2, Siwon Kim2,3, Bo Ko Jang2, Hyung Ho Yoon4, Jun Young Heo1,5, Doo-Wan Cho6, Young-Su Yang6, Su-Cheol Han6, Sangwook Kim7, Soo-Jin Oh1, Sang Ryong Jeon4, Ki Duk Park2,3*, C. Justin Lee1,8* 1Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea, 2Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, KIST, Seoul 02792, Republic of Korea, 3Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792 Republic of Korea, 4Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 5Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea, 6Jeonbuk Branch Institute, Korea Institute of Toxicology, Jeonbuk 56212, Republic of Korea, 7Neurobiogen, Gyeonggi- do 13201, Republic of Korea, 8Center for Cognition and Sociality, Institute for Basic Science, Daejeon 34126, Republic of Korea, Republic of Korea * To whom correspondence should be addressed. Ki Duk Park, TEL: +82-2-958-5132; FAX: +82-2-958-6999; E-mail: [email protected] C. Justin Lee, TEL: +82-42-878-9150; FAX: +82-42-878-9151; E-mail: [email protected] Running Title: KDS2010 for Parkinson’s disease Keywords: MAO-B inhibitor; MPTP; Reactive glia; Parkinson’s disease 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190579; this version posted July 7, 2020.
    [Show full text]
  • Mechanisms of Vesicular Monoamine Transporter-2 Degradation
    MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION by Erin Kathleen Stachowski B.A., University of Rochester, 2006 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Erin Kathleen Stachowski It was defended on November 7, 2016 and approved by Edda Thiels, PhD, Associate Professor, Dept. Neurobiology Alexander Sorkin, PhD, Professor, Dept. Cell Biology Jeffrey Brodsky, PhD, Professor, Dept. Biological Sciences Teresa Hastings, PhD, Associate Professor, Dept. Neurology Habibeh Khoshbouei, PharmD, PhD, Associate Professor, Univ. Florida, Dept. Neuroscience Dissertation Advisor: Gonzalo Torres, PhD, Associate Professor, Univ. Florida, Dept. Pharmacology and Therapeutics ii Copyright © by Erin Kathleen Stachowski 2016 iii MOLECULAR MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION Erin Kathleen Stachowski, PhD University of Pittsburgh, 2016 The vesicular monoamine transporter-2 (VMAT2) packages monoamines into synaptic vesicles in the central nervous system. Not only vital for monoaminergic neurotransmission, VMAT2 protects neurons from cytosolic dopamine-related toxicity by sequestering dopamine into vesicles. This dissertation research is focused on determining the basic mechanisms of VMAT2 degradation—an unexplored aspect of VMAT2 regulation. The processes of protein synthesis and degradation balance to maintain proteostasis. As VMAT2 availability and function directly impact monoamine neurotransmission, its degradation is an important aspect of VMAT2 maintenance to study. While it has been proposed that VMAT2 is degraded by the lysosome, an acidic membrane-bound organelle, there is no direct evidence demonstrating this. In a PC12 cell model system stably expressing VMAT2-GFP, pharmacological tools were used to determine the impact of inhibiting pieces of cellular degradation machinery (the lysosome or the 26S proteasome) on VMAT2.
    [Show full text]
  • Mptp Is Used
    PLEASE POST THIS SUMMARY IN AREAS WHERE MPTP IS USED UNIVERSITY OF CALIFORNIA SAN FRANCISCO ENVIRONMENT, HEALTH AND SAFETY/BIOSAFETY MPTP EXPOSURE/INJURY RESPONSE PROTOCOL FOR USE IN RESEARCH LABORATORIES Organism or Agent: MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) Exposure Risk: Parkinson’s Disease like syndrome UCSF Occupational Health Services: 415/885-7580 (Available during work hours) Office of Environment, Health & Safety: 415/476-1300 (Main number; available during work hours) 415/476-1414 or 9-911 (In case of emergency, via the UCSF Police Department; available 24 hours) EH&S Public Health Officer: 415/476-1722 Biosafety Officer: 415/514 - 2824 Exposure Hotline: 415/353-7842 (Available 24 hours) ______________________________________________________________________________________ PROTOCOL SUMMARY In the event of an accidental exposure or injury, the protocol is as follows: 1. Modes of Exposure: • High Risk Exposures a. Skin puncture or injection b. Ingestion of MPTP c. Inhalation of MPTP powder d. Contact with mucous membranes (eyes, nose, mouth) e. Contact with non-intact skin • Low Risk/Potential Exposure: a. Contact with animal bedding within 72 hours of animal exposure to MPTP b. Percutaneous contact with body fluids from a recently exposed animal c. Contact with intact skin 2. Immediate First Aid: • Skin Exposure: Immediately go to the sink and thoroughly wash the wound with soap and water for 10-15 minutes. • Skin Wound: Immediately go to the sink and thoroughly wash the wound with soap and water for 3 minutes then pat dry. If possible, continue to wash for 10-15 minutes while calling the Exposure Hotline, 415/353-7842, or go to the Emergency Department in case of severe injury.
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]